US2018125884A1PendingUtilityA1
Microporous zirconium silicate for the treatment of hyperkalemia
Est. expiryFeb 11, 2031(~4.6 yrs left)· nominal 20-yr term from priority
A61P 3/14A61P 9/00A61P 7/10A61P 9/04A61P 9/06A61P 3/12A61P 7/00A61P 7/08C01P 2002/72B01J 2219/00063C01B 33/20C01P 2004/61A61K 45/06B01J 2219/00768C01B 39/02C01B 39/46B01J 39/14B01J 2219/00094A61K 33/00B01J 19/18C01B 39/00B01J 19/0066C01P 2004/52B01J 19/006C07F 7/025Y10T428/2982B01J 39/02B01J 19/0013A61K 9/143A61K 9/14C01P 2002/82A61K 2300/00A61K 33/24C01B 39/06C01G 25/00A61K 33/244
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Claims
exact text as granted — not AI-modified1 - 46 . (canceled)
47 . A method for removing potassium from a patient in need thereof comprising administering a potassium-binding particle in an oral dosage form to the patient, the potassium binding particle comprising a microporous material, the particle having an average in vitro binding capacity of at least about 2.5 mmol per gram for binding potassium, and the patient being administered a dose from about 0.050 grams per day to about 33 grams per day.
48 . The method of claim 47 , wherein the dose is from about 0.5 grams per day to about 15 grams per day.
49 . The method of claim 47 , wherein the dose is from about 5 grams per day to about 20 grams per day.
50 . The method of claim 47 , wherein the dose is from about 5 grams per day to about 15 grams per day.
51 . The method of claim 47 , wherein the dose is from about 10 grams per day to about 20 grams per day.
52 . The method of claim 47 , wherein the dose is from about 10 grams per day to about 15 grams per day.
53 . The method of claim 47 , wherein the potassium-binding particle has an average in vitro binding capacity of at least about 3.5 mmol per gram.
54 . The method of claim 47 , wherein the microporous material having a capacity for binding potassium comprises a zirconium silicate.
55 . A method of treating hyperkalemia in a patient in need thereof comprising administering a potassium-binding particle in an oral dosage form to the patient, the potassium-binding particle comprising a microporous material, the particle having an average in vitro binding capacity of at least about 2.5 mmol per gram for binding potassium, and the patient being administered a daily dose from about 0.050 grams per day to about 33 grams per day.
56 . The method of claim 55 , wherein the dose is from about 0.5 grams per day to about 15 grams per day.
57 . The method of claim 55 , wherein the dose is from about 5 grams per day to about 20 grams per day.
58 . The method of claim 55 , wherein the dose is from about 5 grams per day to about 15 grams per day.
59 . The method of claim 55 , wherein the dose is from about 10 grams per day to about 20 grams per day.
60 . The method of claim 55 , wherein the dose is from about 10 grams per day to about 15 grams per day.
61 . The method of claim 55 , wherein the potassium-binding particle has an average in vitro binding capacity of at least about 3.5 mmol per gram.
62 . The method of claim 55 , wherein the microporous material having a capacity for binding potassium comprises a zirconium silicate.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.